The strong anti-tumoral activities of inhibitors for HDAC family members, AURKA, BET/bromodomain-containing proteins, MDM2, MAP2K1 (formerly MEK) and CDK4/6 observed in preclinical neuroblastoma models11, 12, 13, 14, 15, 16 suggest that further drugs will enter pediatric phase I testing in the near future. Here, HDAC9 is linked to neuroblastoma.